<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Fresenius Medical Care AG（FMS,FME.DE）的股票在德國交易中下跌約 4%，在紐約證券交易所的盤前交易中也出現類似情況，此前該公司報告第一季度利潤和收入下降。此外，這家德國腎病患者產品和服務的供應商維持了 2026 財年的展望。</p>
<p>在第一季度，歸屬於股東的淨收入從去年的 1.51 億歐元下降 22%，降至 1.18 億歐元。基本每股收益從去年的 0.52 歐元下降 17%，降至 0.43 歐元。</p>
<p>調整後的淨收入為 2.51 億歐元，或每股 0.91 歐元，而去年同期為 2.46 億歐元，或每股 0.84 歐元。</p>
<p>在第一季度，集團營業收入從去年下降 14%，降至 2.86 億歐元，利潤率從去年的 6.8% 降至 6.2%。</p>
<p>調整後的營業收入增長 2%，達到 4.67 億歐元，調整後的營業利潤率從去年的 9.4% 提高至 10.1%。</p>
<p>集團收入從去年的 48.8 億歐元下降 6%，降至 46.1 億歐元。按固定匯率計算，收入增長 3%，而按有機基礎計算，增長 4%，所有運營部門均實現增長。</p>
<p>展望 2026 財年，Fresenius Medical Care 預計調整後的營業收入將保持在一個穩定水平，預計與去年相比的增長率在正負中間個位數百分比之間。</p>
<p>預計收入增長與去年相比仍將基本持平。2026 年的預期增長率為固定匯率。</p>
<p>在 2025 財年，調整後的營業收入為 22.12 億歐元，收入為 196.28 億歐元。</p>
<p>該公司補充説，預計在 2026 年將節省 2.5 億歐元，併產生 3.5 億歐元的一次性費用。FME25+ 節省預計到 2027 年底將總計達到 12 億歐元。</p>
<p>在德國 XETRA 市場，股票交易價格為 37.24 歐元，下跌 4.2%。</p>
<p>在紐約證券交易所的盤前交易中，股票交易價格為 21.68 美元，下跌 4.3%。</p>
<p>有關更多收益新聞、收益日曆和股票收益，請訪問 rttnews.com。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

<p>Fresenius Medical Care AG 報告第一季度淨收入下降 22%，導致其股價下跌 4%。淨收入降至 1.18 億歐元，基本每股收益降至 0.43 歐元。集團收入下降 6%，至 46.1 億歐元，儘管調整後的營業收入增長了 2%。該公司維持其 2026 財年的展望，預計調整後的營業收入將保持穩定，收入增長持平。其股票在德國交易價格為 37.24 歐元，在紐約證券交易所為 21.68 美元，均下跌約 4%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Shares of Fresenius Medical Care AG (FMS,FME.DE) were losing around 4 percent in German trading as well as in pre-market activity on the NYSE, after the company reported lower profit and revenues in its first quarter. Further, the German provider of products and services for patients with renal diseases maintained fiscal 2026 outlook.</p>
<div class="lb-trans"><p>Fresenius Medical Care AG（FMS,FME.DE）的股票在德國交易中下跌約 4%，在紐約證券交易所的盤前交易中也出現類似情況，此前該公司報告第一季度利潤和收入下降。此外，這家德國腎病患者產品和服務的供應商維持了 2026 財年的展望。</p>
</div><p>In the first quarter, net income attributable to shareholders decreased 22 percent to 118 million euros from last year's 151 million euros in the prior year. Basic earnings per share fell 17 percent to 0.43 euro from 0.52 euro a year ago.</p>
<div class="lb-trans"><p>在第一季度，歸屬於股東的淨收入從去年的 1.51 億歐元下降 22%，降至 1.18 億歐元。基本每股收益從去年的 0.52 歐元下降 17%，降至 0.43 歐元。</p>
</div><p>Adjusted net income was 251 million euros or 0.91 euro per share, compared to 246 million euros or 0.84 euro per share a year earlier.</p>
<div class="lb-trans"><p>調整後的淨收入為 2.51 億歐元，或每股 0.91 歐元，而去年同期為 2.46 億歐元，或每股 0.84 歐元。</p>
</div><p>In the first quarter, Group operating income decreased 14 percent from last year to 286 million euros, resulting in a margin of 6.2 percent, down from 6.8 percent last year.</p>
<div class="lb-trans"><p>在第一季度，集團營業收入從去年下降 14%，降至 2.86 億歐元，利潤率從去年的 6.8% 降至 6.2%。</p>
</div><p>Adjusted operating income increased 2 percent to 467 million euros, and adjusted operating margin improved to 10.1 percent from 9.4 percent last year.</p>
<div class="lb-trans"><p>調整後的營業收入增長 2%，達到 4.67 億歐元，調整後的營業利潤率從去年的 9.4% 提高至 10.1%。</p>
</div><p>Group revenue decreased 6 percent to 4.61 billion euros from 4.88 billion euros a year ago. Revenues increased 3 percent at constant currency, while the growth was 4 percent on an organic basis with growth in all operating segments.</p>
<div class="lb-trans"><p>集團收入從去年的 48.8 億歐元下降 6%，降至 46.1 億歐元。按固定匯率計算，收入增長 3%，而按有機基礎計算，增長 4%，所有運營部門均實現增長。</p>
</div><p>Looking ahead for fiscal 2026, Fresenius Medical Care expects adjusted operating income to remain on a consistent level, with a range between a positive and negative mid-single digit percent growth rate compared to prior year.</p>
<div class="lb-trans"><p>展望 2026 財年，Fresenius Medical Care 預計調整後的營業收入將保持在一個穩定水平，預計與去年相比的增長率在正負中間個位數百分比之間。</p>
</div><p>Revenue growth is still projected to be broadly flat compared to prior year. The expected growth rates for 2026 are at constant currency.</p>
<div class="lb-trans"><p>預計收入增長與去年相比仍將基本持平。2026 年的預期增長率為固定匯率。</p>
</div><p>In fiscal 2025, adjusted operating income was 2.212 billion euros and revenue was 19.628 billion euros.</p>
<div class="lb-trans"><p>在 2025 財年，調整後的營業收入為 22.12 億歐元，收入為 196.28 億歐元。</p>
</div><p>The firm added that it expects 250 million euros savings and 350 million euros related one-time costs in 2026. FME25+ savings are expected to total 1.2 billion euros by the end of 2027.</p>
<div class="lb-trans"><p>該公司補充説，預計在 2026 年將節省 2.5 億歐元，併產生 3.5 億歐元的一次性費用。FME25+ 節省預計到 2027 年底將總計達到 12 億歐元。</p>
</div><p>On the XETRA in Germany, the shares were trading at 37.24 euros, down 4.2 percent.</p>
<div class="lb-trans"><p>在德國 XETRA 市場，股票交易價格為 37.24 歐元，下跌 4.2%。</p>
</div><p>In pre-market activity on the NYSE, the shares were trading at $21.68, down 4.3 percent.</p>
<div class="lb-trans"><p>在紐約證券交易所的盤前交易中，股票交易價格為 21.68 美元，下跌 4.3%。</p>
</div><p>For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.</p>
<div class="lb-trans"><p>有關更多收益新聞、收益日曆和股票收益，請訪問 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

費森尤斯醫療護理第一季度業績下滑，但仍維持 2026 財年展望；股價下跌